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Chromosomal instability (CIN) is a common characteristic in testicular germ cell tumour (TGCT). A functional mitotic checkpoint control is
important for accurate chromosome segregation during mitosis. Mitotic arrest deficient 2 (MAD2) is a key component of this checkpoint and
inactivation of MAD2 is correlated with checkpoint impairment. The aim of this study was to investigate the function of mitotic checkpoint
control in TGCT cells and to study its association with MAD2 expression using 8 TGCT cell lines as well as 23 TGCT tissue samples. We found
that in response to microtubule disruption, 6 of 8 TGCT cell lines (75%) failed to arrest in mitosis demonstrated by the decreased mitotic index and
aberrant expression of mitosis regulators, indicating that mitotic checkpoint defect is a common event in TGCT cells. This loss of mitotic
checkpoint control was correlated with reduced MAD2 protein expression in TGCT cell lines implicating that downregulation of MAD2 may play
a critical role in an impaired mitotic checkpoint control in these cells. In addition, immunohistochemistry studies on 23 seminomas and 12 normal
testis tissues demonstrated that nuclear expression of MAD2 was much lower in seminomas (p<0.0001) but cytoplasmic MAD2 expression was
higher in seminomas (p=0.06) than normal samples. Our results suggest that aberrant MAD2 expression may play an essential role in a defective
mitotic checkpoint in TGCT cells, which may contribute to CIN commonly observed in TGCT tumours.
© 2007 Elsevier B.V. All rights reserved.Keywords: Testicular germ cell tumour; MAD2; Mitotic checkpoint1. Introduction
Chromosomal instability (CIN), a phenotype which cell
division is accompanied by an abnormally high rate of
chromosome losses and gains (aneuploidy), is a hallmark of
cancers [1]. However, the mechanisms and molecular determi-
nants of CIN are not fully understood. In spite of this, recent
research has been suggested that defects in mitotic checkpoint
control may play a key role in aneuploidy and tumorigenesis
[2]. The mitotic checkpoint, also known as spindle assembly
checkpoint, detects errors occurred in the spindle structure or in⁎ Corresponding author. Department of Anatomy, Laboratory Block, Li Ka
Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road,
Hong Kong, SAR, China.
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doi:10.1016/j.bbamcr.2007.03.014the alignment of the chromosomes on the spindle, and delays
chromosome segregation and anaphase onset until the defects
are corrected [2,3]. Two main groups of mitotic checkpoint
proteins, budding uninhibited by benomyl (Bub)1–3 and
mitotic arrest deficient (MAD)1–3, have been suggested to
play key roles in mitotic checkpoint control [3]. The function of
these proteins is to inhibit the activity of anaphase promoting
complex and thus prevent the exit from mitosis in response to
disruption of the spindles [3,4]. Among these proteins, MAD2
is demonstrated to be one of the key components of the mitotic
checkpoint [3]. For example, microinjection of anti-MAD2
antibodies into HeLa cells abolished nocodazole-induced
mitotic arrest and caused premature mitosis [5,6]. In addition,
chromosome missegregation was found in cells generated from
MAD2 knockout mice [7] and deletion of one MAD2 allele
resulted in an impaired mitotic checkpoint in both human colon
822 M.K.-L. Fung et al. / Biochimica et Biophysica Acta 1773 (2007) 821–832cancer cells and murine primary embryonic fibroblasts [8].
These lines of evidence suggest that MAD2 may play vital roles
in CIN and tumorigenesis.
Despite the potential roles of mitotic checkpoint defect
and MAD2 inactivation in CIN, their association with human
tumorigenesis is incompletely understood. Defects in mitotic
checkpoint control have been observed in various cancers.
For instance, high percentage of colon [9], lung [10], ovarian
[11] and oral [12] cancer cells as well as nasopharyngeal
[13] and hepatocellular [14] carcinoma cells fail to arrest in
mitosis in response to microtubule disruption. In addition, a
weak mitotic checkpoint is correlated with an increase in
aneuploid cells with features of oncogenicity in cell culture
and animal models [15], indicating its role in the develop-
ment of CIN and tumorigenesis. Moreover, it has been
demonstrated that mitotic checkpoint defects are correlated
with CIN in human breast cancer [16] and murine T-cells
[17]. Recently, a study has also noted that germline mu-
tations in a checkpoint gene, BuB1B, correlate with a human
disease called mosaic variegated aneuploidy which is
associated with childhood cancer and frequent chromosomal
gains and losses [18]. All these reports support a causal link
between mitotic checkpoint defects, aneuploidy and tumour
development. Meanwhile, the relationship between MAD2
and mitotic checkpoint has been demonstrated in various
types of human cancer and mice models. For example,
aberrantly attenuated MAD2 expression has been associated
with a defective mitotic checkpoint in breast [5,19], ovarian
[11], nasopharyngeal [13] and hepatocellular [14,20] carci-
noma cells. It is further illustrated that induced expression of
MAD2 in checkpoint-defective ovarian cancer cells leads to
restoration of mitotic checkpoint function [11]. In addition, it
has been suggested that MAD2 haplo-insufficiency may lead
to defects in mitotic checkpoint and tumorigenesis [8]. How-
ever, mutations or deletions of the MAD2 gene are found to be
rare in human bladder [21], breast [19,22], digestive tract [23],
liver [20,21] and lung [10] cancers, indicating that alterations of
the MAD2 gene in epigenetic or translation level may be
responsible for its inactivation. Collectively, these studies im-
plicate a subtle link between decreased MAD2 expression and
impaired mitotic checkpoint defects as well as chromosome
instability.
Testicular germ cell tumour (TGCT) is the most frequent
solid malignant tumour diagnosed in men aged 20–40 years
old and accounts for up to 60% of all malignancies diagnosed
at this age [24]. The most common types are seminomas and
non-seminomas [25] which originate from a precursor lesion,
carcinoma in situ (CIS) [26]. One of the striking features of
these tumours is their consistent aneuploidy, most likely
because of the early establishment of polyploidy, although
mechanisms responsible for this phenotype are unknown.
Seminomas have a mean hypertriploid DNA index, whereas
non-seminomas have a mean hypotriploid DNA index,
possibly due to net loss of chromosomal material during
cancer progression [24]. Additionally, aneuploidic events and
extensive CIN play crucial roles in transformation of CIS into
invasive TGCT of both seminomas and non-seminomas [24].Since microsatellite instability is observed in only one third of
TGCT, aneuploidy and chromosome instability are considered
as the most important genetic alterations in TGCT develop-
ment [27]. However, the function of mitotic checkpoint
control and the expression of mitotic checkpoint regulators
have not been reported in this cancer.
The aim of this study was to investigate the competence of
mitotic checkpoint and its association with MAD2 protein
expression in TGCT cells. We demonstrated that defects in
mitotic checkpoint were frequently found in TGCT cells
which were correlated with reduced MAD2 expression in 8
TGCT cell lines. In addition, using immunohistochemistry, we
also examined MAD2 expression in 23 cases of seminoma
and 12 cases of normal testis tissue samples and found
aberrant MAD2 expression in seminoma tissues. Our results
suggest that attenuated MAD2 expression in TGCT cells may
play a vital role in a defective mitotic checkpoint which may
contribute to CIN and tumorigenesis in TGCT.2. Materials and methods
2.1. Cell lines and cell culture conditions
The origins and details of the TGCT cell lines have been described
previously [28]. A nasopharyngeal carcinoma cell line, CNE1 [29], was used as
a positive control for mitotic checkpoint competent cells. Four TGCT cell lines
[GH, 833 K, SuSa, GCT27] and CNE1 were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS) and
penicillin/streptomycin. Three TGCT cell lines [1411HP, NT2/D1, 2102EP]
were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS
and penicillin/streptomycin, and the NCCITcell line was cultured in RPMI 1640
supplemented with 10% FBS and penicillin/streptomycin. All cell lines were
cultured at 37 °C in a humidified atmosphere with 5% CO2.
2.2. Transfection
pLentiviral vector containing short hairpin interfering RNA (shRNA)
against MAD2 mRNA (5′-AATACGGACTCACCTTGCTTG-3′) sequence
(MAD2 shRNA) was constructed using BLOCK-iT Lentiviral RNAi
Expression System (Invitrogen, Carlsbad, CA). A vector expressing control
shRNA sequence (5′-GCGTATTGCCTAGCATTAC-3′), which has no
significant homology to any coding sequences in human genome, was used
as a vector control. The resulting vectors were then transfected into GH cells
using Fugene 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN)
according to manufacturer's manual. For HA-tagged MAD2 plasmid (HA-
tagged MAD2), a ∼1.6-kb fragment containing HA-tagged full length MAD2
cDNA was also cloned to pLenti6/V5-D-TOPO expression vector by TOPO
cloning reaction (Invitrogen, Carlsbad, CA). For control experiments, cells
were transfected with pLenti6/V5-D-TOPO expression vector alone. The
resulting vectors were then transfected into 1411HP cells using Fugene 6
Transfection Reagent (Roche Diagnostics, Indianapolis, IN) according to
manufacturer's manual.
2.3. Patients and specimens
The normal and seminoma specimens were collected from Queen Mary
Hospital in Hong Kong from 2002 to 2003 and from 1993 to 2004
respectively. Testes with no significant pathology from 12 patients diagnosed
with prostate carcinoma were used and they were employed as normal testis
specimens. The patients' age ranged from 69 to 81 years old with a mean of
75.3 years. All 23 tumour specimens were confirmed pathologically to be
seminoma. The patients' age ranged from 24 to 67 years old with a mean of
37.7 years.
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Eight to twenty-four thousand cells were plated onto 12-well plates
depending on plating efficiency and grown for 24 h. They were either treated
with 50 nM nocodazole (Sigma, St. Louis, Missouri) or 0.1 μg/ml colcemid
(Sigma, St. Louis, Missouri) for up to 48 h. Three photos were taken under a
light microscope (Nikon, Japan) at several indicated time points. The presence
of rounded-up cell morphology was considered to be cells undergoing mitotic
arrest as previously suggested [5]. Mitotic index was calculated based on the
percentage of viable cells arrested in mitosis. At least 500 cells were counted for
each experiment using a light microcopy under ×100 or ×200 magnification.
The data points represented the average results from three independent
experiments and the error bars indicated standard derivation.
2.5. Determination of mitotic index by 4',6-diamidino-2-phenylindole
(DAPI) staining
Cells (8000 cells) were grown onto chamber slides (28 mm2) (MP
Biomedicals, Germany) overnight. After treatment with 50 nM nocodazole
(Sigma, St. Louis, Missouri) or 0.1 μg/ml colcemid (Sigma, St. Louis,
Missouri) for 16 h, the cells were fixed in cold 70% methanol and finally to
100% cold methanol. Then the cells were washed with phosphate buffered
saline (PBS) and stained with DAPI for 5 min at room temperature. Finally,
the cells were mounted in fluorescent mounting medium (Sigma, St. Louis,
MO) and viewed under a fluorescent microscope. The presence of condensed
nuclear DNA indicates a mitotic cell. At least 500 cells were counted for each
experiment. Mitotic index was calculated based on the percentage of viable
cells arrested in mitosis. At least 500 cells were counted for each experiment
using a fluorescent microcopy under ×100 or ×200 magnification. The data
points represent the average results from 3 independent experiments and the
error bars indicate the standard derivation.
2.6. Cell cycle analysis
Cells (2.5×105) were plated in culture medium. After 24 h, 50 nM
nocodazole (Sigma, St. Louis, Missouri) was added and incubated for 16 h.
Both floating and attached cells were collected and then fixed in ice-cold 70%
ethanol. The cells were washed with PBS and stained with propidium iodide
(50μg/ml) and RNase (1 μg/ml) for 30 min. Flow cytometric analysis was
done on EPICS profile analyzer and analyzed using ModFit LT2.0 software
(Coulter).
2.7. Western blotting analysis
Total cell lysates were prepared by suspending cell pellets in lysis
buffer [50 mmol/L Tris–HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 0.5%
sodium deoxycholate, and 0.1% SDS] containing proteinase inhibitors
(1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 mmol/L phenylmethylsulfonyl
fluoride) and phosphatase inhibitors (10 mmol/L sodium fluoride and
5 mmol/L sodium orthovanadate). To prepare cytoplasmic fractions, the cell
pellets were suspended in buffer containing 1.5 mM HEPE (pH 7.9),
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1 mM Na3VO4, 0.2% NP40
and the above proteinase inhibitors. Then, the cells were centrifuged at
750 g; the supernatants were saved as the cytoplasmic fractions. The
pellets were resuspended into buffer containing 50 mM Tris–HCl (pH 8.0),
500 mM NaCl, 5 mM EDTA, 0.5 mM DTT, 1 mM Na3VO4, 1% NP40
and the above proteinase inhibitors. The cell pellets were centrifuged at
14,000 g. The supernatants were saved as the nuclear fractions. Protein
concentration was measured using a DC Protein Assay kit (Bio-Rad,
Hercules, CA). Same amount of protein was loaded onto a SDS-
polyacrylamide gel for electrophoresis and then blotted onto a nitrocellulose
membrane (Amersham, Piscataway, NJ). After blocking the membrane with
10% nonfat milk in Tris buffered saline with 0.1% Tween 20 (TBST) for
1 h, the membrane was incubated with primary antibodies for 1 h at room
temperature against 1:1000 MAD2 (BD Transduction Laboratories, Franklin
Lakes, NJ), 1: 500 MAD1 (a gift from Prof, DY Jin), 1:500 Bub1, 1:500
Bub3, 1:500 BuBR1, 1:1000 cyclin A, 1:1000 cyclin B1, 1:1000 histoneH1, 1:1000 actin (Santa Cruz Biotechnology, Santa Cruz, CA) or 1:200
phospho-Histone H3 (Ser10) (Upstate Biotechnology, Lake Placid, NY). Then,
the membrane was incubated with suitable secondary antibodies against mouse
immunoglobulin G, rabbit immunoglobulin G or goat immunoglobulin G
(Amersham, Piscataway, NJ). Signals were visualized by enhanced chemilu-
minescence Western blotting system (Amersham, Piscataway, NJ). Expression
of actin was tested as an internal loading control. The relative intensity of
MAD2 was quantified as relative to that of the positive control cell line,
CNE1.
2.8. Immunofluorescence staining
Cells were grown onto chamber slides (28 mm2) (MP Biomedicals,
Germany) overnight. They were then treated with 50 nM nocodazole or
0.1 μg/ml colcemid for 24 h. Next, the cells were fixed in 70% cold methanol
at 4 °C for 5 min followed by 100% methanol at 4 °C for 5 min. The cells
were then rehydrated in phosphate buffered saline (PBS) for 5 min. After
blocking in 1% bovine serum albumin (Calbiochem, San Diego, CA) for
15 min, the slides were incubated with a 1:40 diluted anti-α-tubulin antibody
(clone B-5-1-2; Sigma, St. Louis, Missouri) for an hour. Afterwards, the
slides were incubated with a FITC-conjugated goat anti-mouse IgG secondary
antibody (Dako, Carpinteria, CA) for an hour. The cells were then counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) when necessary to
visualize the nucleus. Fluorescent signals were visualized on a Zeiss
Axiophot microscope (Carl Zeiss, Germany) and photographed using Spot
RT digital camera and associated software (Diagnostic Instrument, Sterling
heights, MI) under ×1000 magnification.
2.9. MAD2 immunohistochemistry on human tissues
Immunohistochemical staining was carried out on 4 μm sections from
paraffin-embedded specimens. After deparaffinization and rehydration, the
slides were immersed in 0.6% H2O2 for 30 min to block endogenous
peroxidase activity. Antigen retrieval was performed with a microwave oven
as follows: the slides were immersed in pre-warmed 10 mM citrate buffer, pH
6.0, at high power level for 2 min and at medium-high power level for
10 min. Vectastain® Elite ABC Kit (ABC kit) was used according to the
manufacturer's manual (Vector Laboratories, Inc, Burlingame, CA). Briefly,
non-specific binding of the antibody was blocked by 10% normal horse
serum provided in the ABC kit for 20 min. Next, the slides were incubated
with a 1:50 diluted MAD2 antibody (BD Transduction Laboratories, Franklin
Lakes, NJ) in 10% normal horse serum at 4 °C overnight. They were then
incubated with biotinylated secondary antibody provided in the ABC kit for
an hour and finally incubated with the ABC reagent provided in the ABC kit
for 30 min at room temperature. Signals were visualized with diaminobenzi-
dine (DAB) (Dako, Carpinteria, CA). Cells were counterstained with Mayer's
hematoxylin, dehydrated and mounted. MAD2 positive expression was stained
as brown signals in both nucleus and cytoplasm.
2.10. Quantification of immunohistochemical staining
MAD2 protein expression in seminomas and normal testis tissues was
visualized using a light microscope, and three images of ×200 magnification
were captured from each sample. DAB intensity (MAD2 expression level) from
these images was quantified using LEICA QWin image analysis (Leica,
Cambridge, England). All samples were screened and scored in a blinded
manner i.e. without assessing patient information. Mean nuclear intensity, mean
cytoplasmic intensity and mean total (nuclear+cytoplasmic) intensity were
calculated from the mean of each sample. The mean DAB intensity was then
subjected to statistical analysis.
2.11. Statistical analysis
All statistical analysis was performed using a SPSS 11.5 software (SPSS,
Chicago, IL). Comparison between two groups was performed using Mann–
Whitney U test. A p-value of <0.05 was regarded as statistically significant.
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3.1. Competence of mitotic checkpoint in testicular germ cell
tumour cell lines
Defects in mitotic checkpoint are thought to contribute to
CIN and tumorigenesis [2]. Recently, CIN has been reported in
more than 80% of TGCT tissues and associated with invasive
phenotype of TGCT [24]. However, mechanisms responsible
for CIN in TGCT are not understood. To gain insight on this
issue, we assessed the competence of mitotic checkpoint control
in 8 TGCT cell lines, NCCIT, GH, NT2/D1, 833 K, SuSa,
2102EP, GCT27 and 1411HP after treatment with nocodazole
(50 nM) or colcemid (0.1 μg/ml), which inhibit spindle
assembly by disrupting microtubule through different mechan-
isms. CNE1 cell line was used as a positive control because it
was previously demonstrated to be mitotic checkpoint compe-
tent [13]. As shown in Fig. 1A, in the untreated condition,
CNE1 cells remained flat and adhered to the surface of culture
dishes (panel 1). Following the treatment, majority of CNE1
cells became round in shape (panel 2) which is a characteristicFig. 1. Mitotic indices of TGCT cell lines. CNE1 cells were used as a positive co
microscopic examination of CNE1 (panels 1 and 2), GH (panels 3 and 4) and 1411H
treatment with colcemid (0.1 μg/ml) for 16 h. The presence of rounded-up cell morp
under ×200 magnification for CNE1 and GH cells and ×100 magnification for 141
microscope. CNE1 cells were used as a positive control. Cells were treated with 50 n
4 h intervals up to 48 h. The mitotic index equals to the percentage of viable cells a
treated with either 50 nM nocodazole or 0.1 μg/ml colcemid for 16 h. Results repres
derivations. (E) Representative results of immunofluorescence staining of α-tubulin, a
(panels 2 and 4) exposure to nocodazole (50 nM) for 24 h. Photos were taken unde
colcemid treatment.of mitotic arrested cells [5,30]. Representative photos showing
the morphology of 2 TGCT cell lines, GH and 1411HP cells
before (panels 3 and 5) and after (panels 4 and 6) colcemid
treatment are presented in Fig. 1A. After exposed to colcemid,
high percentage of GH cells (panel 4) were arrested in mitosis
but 1411HP cells (panel 6) failed to arrest, indicating a mitotic
arrest in GH but not 1411HP cells.
The mitotic index of the 8 TGCT cell lines in response to
microtubule disruption was calculated and compared with that
of CNE1 cells. Quantification analysis showed that the positive
control, CNE1 (red), illustrated a marked increase in the
percentage of mitotic arrested cells in response to nocodazole in
a time dependent manner with a peak at 20 h (Fig. 1B). Two
TGCT cell lines, NCCIT (orange) and GH (blue), responded to
nocodazole similarly with gradually increase in the percentage
of mitotic arrested cells from 0 to 12 h or from 0 to 20 h with
peaks at 12 h (>60%) or 20 h (>50%) respectively (Fig. 1B),
indicating a similar mitotic checkpoint response to CNE1 cells.
In contrast, as indicated in Fig. 1B, 6 TGCT cell lines [NT2/D1
(green), SuSa (brown), 833 K (purple), 2102EP (red dotted
line), GCT27 (grey dotted line) and 1411HP (purple dottedntrol with a functional mitotic checkpoint. (A) Representative images of light
P (panels 5 and 6) cells before (panels 1, 3 and 5) and after (panels 2, 4, and 6)
hology was considered to be cells undergoing mitotic arrest. Photos were taken
1 HP cells. (B and C) Mitotic indices of 8 TGCT cell lines revealed by light
M nocodazole (B) or 0.1 μg/ml colcemid (C) for indicated times and analyzed at
rrested in mitosis. (D) Mitotic indices determined by DAPI staining. Cells were
ented means of three independent experiments and error bars indicated standard
subunit of microtubule, in GH and 833 K cells before (panels 1 and 3) and after
r ×1000 magnification. Note that the microtubule network was disrupted after
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cells (10–40%) during the 48 h of treatment. These results
illustrated that these cells were not arrested at mitosis to an
extent comparable to CNE1. These data indicate that 6 of 8
(75%) TGCT cells showed much lower mitotic index in
response to nocodazole relative to CNE1, demonstrating that
mitotic checkpoint is not fully functional in a majority of TGCT
cell lines.
To further confirm these results, the cells were exposed to
colcemid, another microtubule disrupting agent. All the cell
lines seemed to be more sensitive to colcemid than nocodazole
as reflected by higher mitotic indices (Fig. 1C). The percentage
of mitotic arrested CNE1 cells (red) increased notably from 0 to
2 h with a peak at 20 h (>95%) (Fig. 1C). Two TGCT cell lines,
NCCIT (orange) and GH (blue), behaved in a similar way to
CNE1 cells in response to colcemid (Fig. 1C). These findings
confirmed the results generated on the cells treated with
nocodazole, suggesting that these 2 TGCT cell lines exhibited a
similar mitotic checkpoint function as CNE1 cells. Though the
percentage of mitotic arrested cells in NT2/D1 (green), SuSa
(brown) (Fig. 1C) and 2102EP (red dotted line) (Fig. 1C) cell
lines also increased in a time-dependent manner with peaks at
16 to 24 h (45–65%), the mitotic index was much lower than
that of CNE1, NCCIT and GH cells, revealing a less competent
mitotic checkpoint in these cells. Conversely, in 3 TGCT cell
lines, 833 K (purple), GCT27 (grey dotted line) and 1411HP
(purple dotted line) (Fig. 1C), there was not much difference in
the percentage of mitotic cells before and after colcemid
treatment (the peak percentage=∼25%), illustrating that
majority of these cells failed to arrest. In brief, we demonstrated
that 6 of 8 (75%) TGCT cell lines exhibited lower mitotic
indices with reference to CNE1 cells in response to colcemidFig. 2. Fate of cells after mitotic block. Cell cycle distribution of CNE1, NCCwhich agrees with the results from nocodazole treatment
suggesting that majority of TGCT cell lines have a defective
mitotic checkpoint. To further confirm the above findings, we
studied mitotic index by another method, DAPI staining of cells
after 16 h of nocodazole or colcemid treatments (Fig. 1D). We
found that similar to the results presented in Fig. 1B and C, the
cell lines with high MAD2 expression showed a much higher
percentage of cells arrested in mitosis after exposure to both
drugs compared to the cell lines with low levels of MAD2.
These results confirm the findings from light microscopy
studies.
To eliminate the possibility that the failure of mitotic arrest in
TGCT cells was a result of a lack of microtubule disruption in
response to nocodazole or colcemid, we studied the changes in
microtubule structure after nocodazole or colcemid treatment.
The 8 TGCT cell lines were immunostained for α-tubulin, a
subunit of microtubule. Representative photos of GH cells and
833 K cells in the presence or absence of nocodazole are shown
in Fig. 1E. In the untreated GH and 833 K cells, α-tubulin in
microtubule network was arranged in long slender fibers
spreading to the entire cytoplasm (Fig. 1E, panels 1 and 3).
After nocodazole treatment (50 nM), the microtubule networks
of both cell lines were largely disrupted (Fig. 1E, panels 2 and
4). Our results reflected that the doses of nocodazole and
colcemid used were sufficient to cause microtubule disruption;
therefore cells which failed to arrest at mitosis might not be due
to resistance to these agents.
4. Fate of cells after mitotic block
To determine if the mitotic arrested cells re-entered the cell
cycle after exiting mitosis or underwent apoptosis, we assessedIT and GH cell lines after 50 nM nocodazole treatment for 24 and 48 h.
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cells at 24 and 48 h time points (Fig. 2). We found that 24 h after
exposure to nocodazole, all cell lines showed a clear G2/M
phase block (24.8–39.8%), indicating that these cell lines were
arrested in mitosis (Fig. 2). At 48 h posttreatment, a sub-G1
peak was observed in all 3 cell lines, suggesting an increased
apoptosis. However, the apoptosis rate was much higher in the
TGCT cell lines compared to the CNE1 cells, possibly due to
the low apoptosis threshold in testicular cells as previously
reported [31,32].
5. Correlation of mitotic checkpoint with MAD2 expression
Aberrantly attenuated MAD2 protein expression level has
been associated with a defective mitotic checkpoint in several
types of cancers [5,11,13,14]. To further study the mechanism
underlying the defects in the mitotic checkpoint response in
TGCT cells, we examined the expression level of MAD2 in
TGCT cells and investigated whether it was correlated with
mitotic checkpoint competence. CNE1 cells again were
employed as a positive control because they were shown toFig. 3. Correlation of MAD2 expression level and mitotic index in TGCT cell lines.
CNE1 and 8 TGCT cell lines. Results represented means of 3 independent experimen
was transfected into 1411HP cells with increasing doses. Effect of MAD2 overexpre
was used as a control. (C) MAD2 shRNAwas transfected into GH cells with increas
DAPI staining. Control shRNA plasmid was used as a control.express a relatively high level of MAD2 [13]. As shown in Fig.
3A, with reference to CNE1 cells, MAD2 protein expression
was the highest in NT2/D1, NCCIT and GH cells by up to 2.5-
fold (black filled columns), and was intermediate in SuSa and
833 K cells (grey cross columns). However, it was the lowest in
2102EP, GCT27 and 1411HP cell lines (open columns).
Analysis on the association between MAD2 expression and
mitotic index showed that cell lines with highest MAD2
expression (i.e. NCCIT and GH) (Fig. 3A) also had high
percentage of mitotic arrested cells (Fig. 1B–D) whereas cell
lines with lowest MAD2 expression (i.e. 2102EP, GCT27 and
1411HP) (Fig. 3A) exhibited lower percentage of mitotic
arrested cells in response to nocodazole or colcemid (Fig. 1B–
D). Taken together, these results suggest that increased MAD2
expression correlates to a competent mitotic checkpoint control
while lower MAD2 expression is associated with an impaired
mitotic checkpoint response in TGCT cells. In addition, the
degree of competent mitotic checkpoint control seems to be
related to increased MAD2 level.
To further study functional significance of MAD2 expression
in TGCT cells, first, we overexpressed MAD2 in 1411HP cells(A) Representative results of western blotting analysis of MAD2 expression in
ts and error bars indicated standard deviation. (B) A HA-tagged MAD2 plasmid
ssion on mitotic index was determined by DAPI staining. Empty vector plasmid
ing doses. Effect of MAD2 downregulation on mitotic index was determined by
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vector (HA-tagged MAD2) (Fig. 3B) and studied the mitotic
index in response to nocodazole or colcemid treatment. As
shown in Fig. 3B, upregulation of MAD2 was correlated with
increased percentage of mitotic arrested cells in a MAD2-
dependent manner, suggesting that upregulation of MAD2 leads
to the restoration of the mitotic checkpoint. On the other hand,
when we suppressed MAD2 expression by transfecting a
MAD2 shRNA, we found that decreased MAD2 expression in
GH cells was associated with decreased percentage of mitotic
arrested cells after nocodazole or colcemid treatment which was
correlated with decreased MAD2 levels (Fig. 3C). These results
indicate that downregulation of MAD2 leads to the occurrence
of perturbed spindle checkpoint control in GH cells.Fig. 4. Expression of mitotic checkpoint proteins in the nuclear and cytoplasmic fracti
cells were treated with 50 nM nocodazole for 16 h. (A) Western blotting of nuclear an
cells using antibody against MAD2. N and C represent nuclear and cytoplasmic fra
cytoplasmic fractions accordingly. (B) After treatment with nocodazole, the nuclear
were calculated. Note that the N/C of MAD2 expression in NCCIT and GH were hi
MAD1, Bub1, Bub3 and BubR1 in N and C fractions of GH and 833 K cells in resTo our surprise, the cell line 833 K expressed an intermediate
MAD2 level but showed lowest mitotic index after both
nocodazole and colcemid treatment (Fig. 1B–D). Since it has
been reported that an intact spindle checkpoint may require
nuclear congression of MAD2 protein [33], we therefore
physically fractionated the cell lysate into nuclear and
cytoplasmic fractions and probed for MAD2. As shown in
Fig. 4A, after exposure to nocodazole, the nuclear expression of
MAD2 was increased in the two mitotic checkpoint competent
cell lines, NCCIT and GH, which was associated with decreased
cytoplasmic MAD2 expression. In contrast, in 833 K cells, there
was low detectable expression level of MAD2 protein in the
nuclear fraction, even though there was a decreased cytoplasmic
MAD2 protein expression. It is possible that in response toons of NCCIT, GH and 833 K cell in the presence or absence of nocodazole. The
d cytoplasmic extract of nocodazole treated or untreated NCCIT, GH and 833 K
ctions respectively. Histone H1 and actin act as loading control in nuclear and
/cytoplasmic ratios (N/C) of MAD2 expression of NCCIT, GH and 833 K cells
gher than that in 833 K cells in response to nocodazole. (C) The expression of
ponse to nocodazole.
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cytoplasm to the nucleus in order to regulate mitotic arrest. The
nuclear/cytoplasmic ratio (N/C) of MAD2 in response to
nocodazole may be an important indicator of a functional
mitotic checkpoint as we found that the N/C ratio in NCCIT and
GH cells was over 10-fold higher than that of 833 K cells treated
with nocodazole (Fig. 4B). It is possible that the cytoplasmic
MAD2 expression in 833 K cells may not be able to function in
mitotic checkpoint response as suggested previously [33],
explaining the incompetence of mitotic checkpoint control in
these cells.
As mitotic checkpoint consists of many key components
such as MAD2, MAD1, Bub1, Bub3 and BubR1 and all these
proteins are required for mitotic arrest in the presence of
spindle poisons [34], we compared the expression of these
proteins in response to nocodazole in GH and 833 K cells to
see if differential expression of these proteins contribute to
mitotic checkpoint control. MAD1 is required for kinetochore
localization of MAD2 and its binding to cdc20 [35]. Bub1 is
suggested in involving the regulation of MAD1–MAD2
interaction [36]. Bub3 and BubR1 are components of mitotic
checkpoint complex which inhibit cdc20 [36]. As shown in
Fig. 4C, similar to MAD2 expression pattern, nuclear MAD1
expression was increased in response to nocodazole in GH
cells but not in 833 K cells, although decreased cytoplasmic
expression was observed in both cell lines, suggesting that
nuclear MAD1 expression may also play a role in the MAD2
mediated mitotic checkpoint. However, we did not observe
any significant changes in the expression patterns of Bub1,
Bub3 and BubR1 between these two cell lines. Hence, our
results indicate that nuclear migration of MAD1 and MAD2
proteins in response to microtubule disruption may play a key
role in regulating mitotic checkpoint control in TGCT cell
lines. It has been reported that in prometaphase, when mitotic
checkpoint is active, MAD2 localizes to unattached kineto-
chores [5] which may serve as a catalytic device to transform
inactive MAD2 molecules into an active form that can bind to
cdc20 and inhibit the activity of the anaphase-promoting
complex or cyclosome (APC/C) [37–39]. In this study, it is
possible that the MAD2 protein failed to migrate from
cytoplasm to nucleus therefore leading to a failed mitotic
arrest in response to microtubule disruption. It is also possible
that the mislocalization of MAD2 in 833 K cells might be due
to lack of nuclear MAD1 expression since MAD1 is required
for the kinetochore localization of MAD2 and its binding to
cdc20 [36]. However, further experiments are necessary to
confirm this hypothesis.
6. Differential cell cycle protein expression in response to
microtubule disruption in testicular germ cell tumour cell
lines
To further confirm the association between MAD2 expres-
sion and mitotic checkpoint competence, we examined the
expression levels of cyclin B1 and cyclin Awhich are degraded
by anaphase-promoting complex during mitosis [40]. Degrada-
tion of cyclin A begins when cells enter mitosis and to thelowest level before metaphase to anaphase transition [41] while
degradation of cyclin B is required for the transition from
metaphase into anaphase [42]. As shown in Fig. 5B and C, after
exposure to nocodazole and colcemid, CNE1, the mitotic
checkpoint competent cell line, showed a marked accumulation
of cyclin B1 and cyclin A from 4 h and persisted to 16 h post-
exposure. Similar results were found in NCCIT and GH cells
(Fig. 5B and C). We then tested the expression of another
protein, p-Histone H3, phosphorylation of Histone H3 at ser10
is thought to be necessary for chromosome condensation in
mitosis [43]. P-Histone H3 accumulates during prophase with
its peak at metaphase, and then decreases when cells progress
through the cell cycle to telophase. As shown in Fig. 5B and C,
in the 3 cell lines with high MAD2 expression (CNE1, NCCIT,
GH), the levels of p-Histone H3 increased with time after
exposure to nocodazole and colcemid, indicating an accumula-
tion of metaphase cells. In contrast, in GCT27 and 833 K cells,
there was lower levels of p-Histone H3 upregulation (GCT27)
or a delayed accumulation (833 K), suggesting an impaired
response to nocodazole and colcemid-induced mitotic arrest
(Fig. 5B and C). In contrast, the alteration in the expression of
the mitotic related proteins was not significantly altered at the
same time points (Fig. 5A). In conclusion, results from mitotic
index, MAD2 expression level and cell cycle protein profile in
response to microtubule disruption consistently point out that
higher MAD2 expression level is associated with mitotic
checkpoint competence.
The different views of mitosis these cell cycle proteins
addressing may account for the appeared lack of correlation
between the mitotic index and the expression of cyclin A and
p-Histone H3 in the cells. As mitosis can be divided into many
phases from prophase to cytokinesis, the round shaped cells
only present mitotic arrested cells but do not indicate the exact
phase where the cells are in. In contrast, the accumulation and
degradation of cyclin B1, cyclin A and p-Histone H3 reflect
more precisely different phase of mitosis. For example, the high
mitotic index (Fig. 1C) together with the low level of cyclin A
and p-Histone H3 (Fig. 5C) found in colcemid treated CNE1
cells at 16 h might be an indication that the mitotic arrested cells
are in telophase. Likewise, the mitotic index of colcemid treated
GH cells was peaking around 16 h and dropping to almost 0 at
32 h (Fig. 1C) where the p-Histone H3 began to accumulate at
16 h with the largest amount at 48 h (Fig. 5C). The drop in
mitotic index with accumulated high p-Histone H3 level might
indicate that GH cells did not exit mitosis but underwent cell
death after colcemid treatment since p-Histone H3 represents
chromosome condensation that is also observed in apoptotic
cells [44].
7. Differential MAD2 expression between seminoma and
normal testis specimens
To investigate if there was an aberrant MAD2 expression
in TGCT tumour samples, we performed immunohistochem-
ical staining on normal testis tissues (n=12) and seminomas
tissues (n=23). Expression of MAD2 (brown signals) was
found in both nucleus and cytoplasm as indicated by arrows
Fig. 5. Western blot analysis of differential expression of cell cycle proteins in response to microtubule disruption. Differential expression of cyclin B1, cyclin A and
p-Histone H3 in untreated CNE1 cells and 4 TGCTcell lines (A), CNE1 cells and 4 TGCTcell lines treated with 50 nM nocodazole (B) and 0.1 μg/ml colcemid (C) for
indicated time points.
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6A. We observed that there was no significant difference
(p=0.06) in the mean total MAD2 staining intensity between
seminomas and normal testis tissues (Fig. 6B). However, the
mean nuclear intensity was much lower in seminoma
specimens compared to normal tissues (p<0.0001) (Fig.
6C). In addition, we found that the mean cytoplasmic MAD2
staining intensity was higher in seminoma tissues than normal
tissues (p<0.0001) (Fig. 6D). In summary, aberrant MAD2
expression was observed in seminomas with low nuclear
MAD2 expression and high cytoplasmic MAD2 expression
compared with normal tissues.
8. Discussion
CIN has been shown to be an important event in TGCT,
which is associated with oncogenesis, tumour progression [45],
invasive phenotype [24] and drug resistance [46,47]. However,
little is known about the molecular basis of CIN. In this study,
we first identified a high frequency of mitotic checkpoint defect
in TGCT cells (75%; 6 of 8 cell lines) which was in association
with a reduced MAD2 protein expression (Fig. 1B–D and 3A).Additionally, we found decreased nuclear expression of MAD2
in seminomas when compared with normal tissues (Fig. 6). Our
observations point out the critical role of MAD2 for a functional
mitotic checkpoint response in TGCT cell lines and suggest that
a defective mitotic checkpoint may contribute to CIN
commonly observed in TGCT cells.
In the present study, we have shown a high frequency of
mitotic checkpoint defect in TGCT cells (Fig. 1B–D). This is
comparable to data published on human breast cancers where 7
of 9 (77%) cell lines have a defective mitotic checkpoint [16].
Our results support the idea that disturbance of mitotic
checkpoint function may contribute to the development of
cancer [48]. It has been known that aneuploidy and CIN are the
most important features in TGCT development and are
correlated with invasive transformation of TGCT [24]. Our
data on defective mitotic checkpoint in TGCT open up a
possible explanation for the chromosomal abnormalities
commonly seen in advanced TGCT. Our findings also revealed
the correlation between mitotic checkpoint defect and a reduced
MAD2 expression level in TGCT cell lines (Fig. 1B–D; Fig.
3A), indicating the importance of MAD2 in controlling the
mitotic checkpoint function.
Fig. 6. Differential MAD2 expression between seminoma and normal testis specimens. Immunohistochemical staining of MAD2 was carried on human seminoma
tissues and normal testis tissues. (A) Representative photos of MAD2 staining in normal testis (panels 2 and 6) and seminoma tissues with nuclear MAD2 staining
(panels 3 and 7) and cytoplasmic MAD2 staining (panels 4 and 8) in seminoma tissues. Arrows indicate positive-stained cells. Testis tissue stained without primary
antibodies was served as a negative control (panels 1 and 5). Photos were taken under ×200 (panels 1–4) and ×400 (panels 5–8) magnification respectively. (B)
Comparison of mean total MAD2 staining intensity in tumour tissues (indicated as T, shaded column) and normal tissues (indicated as N, open column). (C)
Quantification of mean nuclear MAD2 staining intensity in tumour tissues (indicated as T, shaded column) and normal testis tissues (indicated as N, shaded column).
(D) Illustrative results of mean cytoplasmic MAD2 staining intensity in tumour tissues (indicated as T, shaded column) and normal testis tissues (indicated as N, open
column). The data shown are the mean±standard derivation. The data from each group were subjected to Mann–Whitney U test. Note that mean nuclear MAD2
staining intensity in tumour samples is much lower compared with normal testis samples (p<0.0001) and mean cytoplasmic MAD2 staining intensity in tumour
samples is much higher than normal testis tissues (p<0.0001).
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may lead to mitotic checkpoint defect which in turn contributes
to CIN in TGCT. Immunohistochemistry of MAD2 on
seminomas and normal testis tissues confirmed this hypothesis
and provided the first evidence on attenuated nuclear MAD2
expression (Fig. 6C) and elevated cytoplasmic MAD2 level in
TGCT tumour tissues (Fig. 6D). Since a previous study
suggested that nuclear congression of MAD2 was essential in
a functional mitotic checkpoint [49], the reduced nuclear
MAD2 expression in TGCT tissues may reflect the possibility
that the mitotic checkpoint control may be defective in TGCT
samples. Although mitotic checkpoint becomes active at pro-
metaphase, the nuclear MAD2 expression in the tissue samples
might still have an indication on the competence of the
checkpoint because it has been suggest that localization of
MAD2 in nuclear pore complex may be related to its mitotic
functions [50]. The same study proposes that during nuclearenvelope breakdown, MAD2 may lose their association with the
disassembling nuclear pore complex and be directly transferred
to kinetochores to serve its mitotic checkpoint functions [50].
The increased cytoplasmic MAD2 expression in human TGCT
tissues was similar to the findings from gastric [51] and
colorectal cancer [52,53] However, the cytoplasmic MAD2
expression in cancer tissues may not be able to contribute to a
functional mitotic checkpoint as it was demonstrated in 833 K
cells that the low N/C of MAD2 expression was correlated with
a defective mitotic checkpoint (Fig. 4A and B). In good
agreement with these findings, a previous report revealed that
mislocation of MAD2 from nuclear to cytoplasm correlated
with loss of mitotic checkpoint function in a human T-cell
leukemia virus type I transformed T-cell line [49], further
supporting our suggestion on the significance of nuclear
localization of MAD2 protein in TGCT tissues. Previously,
overexpressions of MAD2 protein or mRNA levels were found
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toma while no consistent findings was reported in neuroblas-
tomas [54]. As the localization of MAD2 was not analyzed, it is
possible that the increased MAD2 protein and mRNA levels
observed in these tumours was mainly the cytoplasmic form
which may not be able to function as a regulator of mitotic
checkpoint. On the other hand, it is also possible that the
significance of nuclear MAD2 expression may be specific to
TGCT cells.
In summary, we have presented a high frequency of mitotic
checkpoint defect in TGCT cells. Furthermore, we have
indicated an association between the loss of mitotic checkpoint
and reduced expression of MAD2 protein in these cells.
Moreover, we have noted an abnormal expression pattern of
MAD2 in human seminomas tissues. Our findings indicate the
importance of MAD2 in mitotic checkpoint control in TGCT
cells and provide a possible explanation for the frequent
chromosomal defects found in TGCT. Based on this study, we
suggest that defects in mitotic checkpoint may contribute to
CIN commonly seen in TGCT. Recently, we have found that
inactivation of MAD2 in TGCT cells correlates with decreased
cellular sensitivity to cisplatin, the most efficient single agent in
the treatment of TGCT [28]. Together with our present study, it
is possible that downregulation of MAD2 may be a potential
marker for identification of TGCT patients resistant to cisplatin-
based therapy which may provide guidance to clinical manage-
ment of TGCT patients. Additionally, a correlation of MAD2
and chemosensitization has also been demonstrated in naso-
pharyngeal carcinoma [55] and ovarian cancer [11] cells. In
combination with current results, these lines of evidence suggest
a general feasibility of MAD2 as an indicator for advanced
TGCT.
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